A cholesterol-dependent LRRC8A-caveolin-1 axis sustains KRAS/EGFR signaling, ribosome biogenesis and growth in pancreatic ductal adenocarcinoma

Submitted by Anonymous on

Cellular adaptive volume regulation is essential for maintaining metabolic homeostasis and supporting survival, yet its role in desmoplastic pancreatic ductal adenocarcinoma (PDAC) remains incompletely understood. Through comprehensive bioinformatic and functional studies, we identified LRRC8A, the core subunit of volume-regulated anion...

Albuminuria, but not eGFR, tracks diabetic retinopathy severity and retinal ischemia: population-based discovery, clinical replication, and OCTA evidence

Submitted by Anonymous on

BackgroundWe investigated whether albuminuria is more consistently associated with diabetic retinopathy (DR) severity than estimated glomerular filtration ra Abstract Background: We investigated whether albuminuria is more consistently associated with diabetic retinopathy (DR) severity than estimated glomerular filtration rate (eGFR) and...

Association between extracellular-to-total body water ratio and eGFR decline in diabetic kidney disease: a longitudinal cohort study

Submitted by Anonymous on

AbstractBackground Diabetic kidney disease (DKD) can progress even in the absence of overt albuminuria, highlighting the need for markers for evaluating nonglomerular pathways. The extracellular-to-total body water ratio (ECW/TBW), measured via bioelectrical impedance analysis (BIA), reflects systemic fluid status; however,...

Histological transformation into pulmonary sarcomatoid carcinoma from lung adenosquamous carcinoma after radical resection of EGFR gene Exon-21 L858R mutation: a case report and literature review

Submitted by Anonymous on

Pulmonary sarcomatoid carcinoma (PSC) is frequently underdiagnosed or misdiagnosed due to its rarity and complex histological features. To date, no universal Introduction The 2021 WHO classification revised this taxonomy, reclassifying sarcomatoid carcinomas into three separate disease entities: pleomorphic carcinoma, pulmonary...

Clinicogenomic analysis of EGFR-mutant lung tumors identifies Rb pathway inactivation as a hallmark of squamous transformation

Submitted by Anonymous on

AbstractHistologic transformation to lung squamous cell carcinoma (LUSC) is an underrecognized mechanism of resistance in epidermal growth factor receptor (EGFR)–mutant lung adenocarcinoma (LUAD). Although AKT and MYC activation have been linked to LUSC features, the clinicogenomic determinants of this transformation...

Multitargeted comparative evaluation suggests 2-Aoeobenoxmide shows favourable in silico binding compared to Tucatinib against ERα, HER2, AKT1, EGFR, and PIK3CA in breast cancer

Submitted by Anonymous on

Breast cancer is a leading cause of cancer-related morbidity and mortality globally, with the WHO reporting approximately 2.3 million new cases and 685,000 deaths annually. Drug resistance in breast cancer complicates treatment, with mutations in critical proteins contributing to therapy...

Case Report: Neoadjuvant chemoimmunotherapy achieving pathological complete response in two cases of stage III EGFR-mutant NSCLC with high PD-L1 expression

Submitted by Anonymous on

Abstract Resectable locally advanced EGFR-mutant non-small cell lung cancer (NSCLC) represents a distinct therapeutic challenge. Owing to an inherently immunosuppressive tumor microenvironment-frequently characterized by absence of or low PD-L1 expression and sparse CD8+ tumor-infiltrating lymphocytes-patients with EGFR alterations have been...

Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial

Submitted by Anonymous on

ArticlesOnline firstJune 16, 2026Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trialProf Ziming Li, MDa,† ∙ Prof Jie Hu, MD PhDb,c,† ∙ Prof Jianhua Chen, MDd ∙ Prof Yan...

Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non–Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial

Submitted by Anonymous on

: The HARMONi-A Randomized Clinical Trial : The HARMONi-A Randomized Clinical Trial : Research Summary : Research Summary Key Points Question Does adding ivonescimab to chemotherapy improve overall survival in patients with epidermal growth factor receptor (EGFR) gene variant non–small...

Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non–Small Cell Lung Cancer: Research Summary

Submitted by Anonymous on

: Research Summary : Research Summary This study assessed whether adding ivonescimab, a bispecific antibody, to chemotherapy improves overall survival for patients with advanced epidermal growth factor receptor (EGFR) gene variant nonsquamous non–small cell lung cancer (NSCLC) after disease progression...

Subscribe to Newsfeed